B. Riley Securities Reiterates Buy on Precigen, Lowers Price Target to $11
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
What Makes Precigen (PGEN) a New Buy Stock
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
Precigen (PGEN) Stock Looks Fully Priced On Current Earnings
Precigen (PGEN) Q3 2026 Earnings Call Transcript
Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12
Precigen Inc (PGEN) Q3 2026 Earnings Call Highlights: Triple-Digit Revenue Surge, First ...
What Precigen (PGEN) Said on Its Q3 Earnings Call
Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Precigen Q3 2026 Earnings Call Transcript
Precigen Q3 EPS $0.08 Beats $0.07 Estimate, Sales $74.148M Beat $71.558M Estimate
Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos?
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings
PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings
PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.